Sitagliptin (Sitagliptin) Patent Expiration, LOE Window & CMS Spending

Sitagliptin (Sitagliptin) by Zydus Pharmaceu: Multi-Source Generic Molecule, 3 AB generics, $3.6M 2024 CMS Part D & Medicaid spend, and $9,504 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorZydus Pharmaceu
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$3.6M
2024 Medicare Part D Spend$3.3M
2024 Medicaid Spend$278K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($9,504 intro WAC)